title: Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
abstract: BACKGROUND
  Recurrent medulloblastoma is a therapeutic challenge because it is almost always fatal. Studies have confirmed that medulloblastoma consists of at least four distinct subgroups. We sought to delineate subgroup-specific differences in medulloblastoma recurrence patterns.
  
  
  METHODS
  We retrospectively identified a discovery cohort of all recurrent medulloblastomas at the Hospital for Sick Children (Toronto, ON, Canada) from 1994 to 2012 (cohort 1), and established molecular subgroups using a nanoString-based assay on formalin-fixed paraffin-embedded tissues or frozen tissue. The anatomical site of recurrence (local tumour bed or leptomeningeal metastasis), time to recurrence, and survival after recurrence were assessed in a subgroup-specific manner. Two independent, non-overlapping cohorts (cohort 2: samples from patients with recurrent medulloblastomas from 13 centres worldwide, obtained between 1991 and 2012; cohort 3: samples from patients with recurrent medulloblastoma obtained at the NN Burdenko Neurosurgical Institute [Moscow, Russia] between 1994 and 2011) were analysed to confirm and validate observations. When possible, molecular subgrouping was done on tissue obtained from both the initial surgery and at recurrence.
  
  
  RESULTS
  Cohort 1 consisted of 30 patients with recurrent medulloblastomas; nine with local recurrences, and 21 with metastatic recurrences. Cohort 2 consisted of 77 patients and cohort 3 of 96 patients with recurrent medulloblastoma. Subgroup affiliation remained stable at recurrence in all 34 cases with available matched primary and recurrent pairs (five pairs from cohort 1 and 29 pairs from cohort 2 [15 SHH, five group 3, 14 group 4]). This finding was validated in 17 pairs from cohort 3. When analysed in a subgroup-specific manner, local recurrences in cohort 1 were more frequent in SHH tumours (eight of nine [89%]) and metastatic recurrences were more common in group 3 and group 4 tumours (17 of 20 [85%] with one WNT, p=0·0014, local vs metastatic recurrence, SHH vs group 3 vs group 4). The subgroup-specific location of recurrence was confirmed in cohort 2 (p=0·0013 for local vs metastatic recurrence, SHH vs group 3 vs group 4,), and cohort 3 (p<0·0001). Treatment with craniospinal irradiation at diagnosis was not significantly associated with the anatomical pattern of recurrence. Survival after recurrence was significantly longer in patients with group 4 tumours in cohort 1 (p=0·013) than with other subgroups, which was confirmed in cohort 2 (p=0·0075), but not cohort 3 (p=0·70).
  
  
  CONCLUSIONS
  Medulloblastoma does not change subgroup at the time of recurrence, reinforcing the stability of the four main medulloblastoma subgroups. Significant differences in the location and timing of recurrence across medulloblastoma subgroups have potential treatment ramifications. Specifically, intensified local (posterior fossa) therapy should be tested in the initial treatment of patients with SHH tumours. Refinement of therapy for patients with group 3 or group 4 tumours should focus on metastases.
authors.affiliation: Division of Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada; Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
authors.forename: Vijay
authors.initials: V
authors.lastname: Ramaswamy
authors.forename: Marc
authors.initials: M
authors.lastname: Remke
authors.forename: Eric
authors.initials: E
authors.lastname: Bouffet
authors.forename: Claudia C
authors.initials: CC
authors.lastname: Faria
authors.forename: Sebastien
authors.initials: S
authors.lastname: Perreault
authors.forename: Yoon-Jae
authors.initials: YJ
authors.lastname: Cho
authors.forename: David J
authors.initials: DJ
authors.lastname: Shih
authors.forename: Betty
authors.initials: B
authors.lastname: Luu
authors.forename: Adrian M
authors.initials: AM
authors.lastname: Dubuc
authors.forename: Paul A
authors.initials: PA
authors.lastname: Northcott
authors.forename: Ulrich
authors.initials: U
authors.lastname: Schüller
authors.forename: Sridharan
authors.initials: S
authors.lastname: Gururangan
authors.forename: Roger
authors.initials: R
authors.lastname: McLendon
authors.forename: Darell
authors.initials: D
authors.lastname: Bigner
authors.forename: Maryam
authors.initials: M
authors.lastname: Fouladi
authors.forename: Keith L
authors.initials: KL
authors.lastname: Ligon
authors.forename: Scott L
authors.initials: SL
authors.lastname: Pomeroy
authors.forename: Sandra
authors.initials: S
authors.lastname: Dunn
authors.forename: Joanna
authors.initials: J
authors.lastname: Triscott
authors.forename: Nada
authors.initials: N
authors.lastname: Jabado
authors.forename: Adam
authors.initials: A
authors.lastname: Fontebasso
authors.forename: David T W
authors.initials: DT
authors.lastname: Jones
authors.forename: Marcel
authors.initials: M
authors.lastname: Kool
authors.forename: Matthias A
authors.initials: MA
authors.lastname: Karajannis
authors.forename: Sharon L
authors.initials: SL
authors.lastname: Gardner
authors.forename: David
authors.initials: D
authors.lastname: Zagzag
authors.forename: Sofia
authors.initials: S
authors.lastname: Nunes
authors.forename: José
authors.initials: J
authors.lastname: Pimentel
authors.forename: Jaume
authors.initials: J
authors.lastname: Mora
authors.forename: Eric
authors.initials: E
authors.lastname: Lipp
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Walter
authors.forename: Marina
authors.initials: M
authors.lastname: Ryzhova
authors.forename: Olga
authors.initials: O
authors.lastname: Zheludkova
authors.forename: Ella
authors.initials: E
authors.lastname: Kumirova
authors.forename: Jad
authors.initials: J
authors.lastname: Alshami
authors.forename: Sidney E
authors.initials: SE
authors.lastname: Croul
authors.forename: James T
authors.initials: JT
authors.lastname: Rutka
authors.forename: Cynthia
authors.initials: C
authors.lastname: Hawkins
authors.forename: Uri
authors.initials: U
authors.lastname: Tabori
authors.forename: Kari-Elise T
authors.initials: KE
authors.lastname: Codispoti
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Packer
authors.forename: Stefan M
authors.initials: SM
authors.lastname: Pfister
authors.forename: Andrey
authors.initials: A
authors.lastname: Korshunov
authors.forename: Michael D
authors.initials: MD
authors.lastname: Taylor
mesh_terms: D000293:Adolescent; D002170:Canada; D002528:Cerebellar Neoplasms / Q000145:classification / Q000235:genetics* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D005060:Europe; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008527:Medulloblastoma / Q000145:classification / Q000235:genetics* / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000145:classification / Q000235:genetics* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D010641:Phenotype; D025341:Principal Component Analysis; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D014481:United States